Based on the statistical evaluations, overall, the optimum cutoff points for the biomarkers explored were set at CD45neg EpCAMpos CTCs (≥3/7 mL), CD45neg EpCAMneg cells ≥ 400/7 mL, and CEA > 5 ng/mL for the prediction of advanced or non-advanced CRC. This evidence concerns the gene CEACAM5 and colorectal carcinoma.